Lantern Pharma Inc.
LTRN
$3.74
-$0.19-4.84%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -7.77% | -11.98% | -6.92% | 2.63% | 11.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.98% | 26.50% | 31.88% | 23.87% | 28.27% |
| Operating Income | -25.98% | -26.50% | -31.88% | -23.87% | -28.27% |
| Income Before Tax | -25.96% | -24.46% | -25.19% | -11.93% | -5.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.96% | -24.46% | -25.19% | -11.93% | -5.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.96% | -24.46% | -25.19% | -11.93% | -5.12% |
| EBIT | -25.98% | -26.50% | -31.88% | -23.87% | -28.27% |
| EBITDA | -25.98% | -26.50% | -31.88% | -23.85% | -28.26% |
| EPS Basic | -27.23% | -25.50% | -25.83% | -12.21% | -5.77% |
| Normalized Basic EPS | -26.91% | -25.16% | -25.48% | -12.52% | -12.88% |
| EPS Diluted | -27.41% | -25.59% | -25.92% | -12.31% | -5.69% |
| Normalized Diluted EPS | -26.91% | -25.16% | -25.48% | -12.52% | -12.88% |
| Average Basic Shares Outstanding | -0.99% | -0.73% | -0.45% | -0.23% | -0.65% |
| Average Diluted Shares Outstanding | -0.99% | -0.73% | -0.45% | -0.23% | -0.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
